Synthetic Lethality of Metabolic Enzymes

A synthetic lethal interaction is a property of a pair.

Four terms, one of which is a pair

TermDefinitionMinimum design
Synthetic lethalSingle perturbation viable in both states; both together lethalTwo states × two perturbations
Synthetic sickSame, but reduced fitness rather than deathSame design, graded readout
SensitisationOne perturbation increases the effect of anotherOne state, two doses
Conditional dependencyRequirement appears only under a condition (genotype, nutrient, drug)Two conditions, one perturbation

Only the first two require the two-by-two. The third and fourth are frequently published as the first, and they are different claims with different biomarker implications: a sensitiser needs a combination strategy; a synthetic lethal needs a genotype-defined population.

Important distinction. "Gene X is essential in MTAP-deleted cells" is a conditional dependency. "Gene X deletion is lethal only when MTAP is also deleted" is a synthetic lethal interaction. The first is compatible with X being essential in both states to different degrees; the second is not.

Why metabolic synthetic lethality is usually conditional

Metabolic enzymes sit in networks with alternative inputs. Whether removing an enzyme is lethal therefore depends on what else is supplied.

Supply routeEffect on the apparent interaction
Salvage pathway presentDe novo synthesis is dispensable regardless of genotype
Nutrient in medium or dietThe dependency disappears when the nutrient is available
Redundant isozymeSingle knockout shows nothing
Compensatory flux through a parallel pathwayEffect is partial and time-dependent
TransportThe cell cannot use an alternative substrate that is present

This is why metabolic synthetic lethality screens find interactions that fail to reproduce in vivo: the interaction was real in the medium and absent in the plasma. The disease pillar makes the same point about dependency generally; for synthetic lethality the consequence is sharper, because the interaction is the product.

The canonical example, and what it teaches

MTAP is frequently co-deleted with CDKN2A. Loss of MTAP causes accumulation of methylthioadenosine (MTA), which partially inhibits PRMT5; the cell survives by a narrow margin. Inhibiting MAT2A reduces S-adenosylmethionine availability and collapses that margin, producing PRMT5-dependent lethality.

ElementWhat it demonstrates
Genotype as biomarkerThe deletion is the selection criterion, measurable before treatment
A metabolic axis, not a single enzymeMTAP–MTA–MAT2A–SAM–PRMT5
A narrow margin, not an absent pathwayThe cell is viable; the interaction exploits the margin
Two directions of evidenceGenetic (MAT2A knockout) and pharmacological (MAT2A inhibitor)

The teaching point is the third row. Most metabolic synthetic lethals are not "pathway present versus absent" but "margin wide versus narrow". That has two consequences: the effect is graded rather than binary, and it is sensitive to anything else that shifts the margin.

Evidence standard

LevelExperimentWhat it establishes
1Panel of cell lines stratified by the genotypeAssociation between genotype and sensitivity
2Isogenic pair (knockout and wild type in the same background)The genotype causes the difference
3Second perturbation (second guide, independent compound)Not a reagent artefact
4Rescue with the deleted gene or the downstream productThe mechanism
5In vivo at achievable exposureThe interaction exists in a tissue

Level 1 alone is the most common and the weakest: a panel correlation is confounded by everything else that differs between lines, including the lineage in which the deletion typically occurs. Level 2 is what most published claims lack, and it is the cheapest of the five.

Caveat on isogenic pairs. An isogenic pair generated by CRISPR knockout of a passenger gene can carry clones with different proliferation rates, different karyotypes and different off-target edits. Two clones per state, plus a second guide, is the minimum that separates the genotype from the clone.

The asymmetry problem

A synthetic lethal pair is symmetric in principle and asymmetric in practice: one gene is the biomarker, the other is the drug target. Getting the direction wrong produces a programme that tests the wrong thing.

DirectionQuestionDecision
Target the deleted geneUsually impossible — it is already absentNot a target
Target the partnerExploit the margin created by the deletionThe usual strategy
Target a downstream nodePRMT5 in the MTAP caseWider effect, narrower window

Important distinction. The biomarker is usually a loss-of-function event, and loss-of-function biomarkers are harder to assay than amplifications or mutations. A deletion call at the boundary between homozygous and heterozygous loss is exactly where the eligible population is decided, and it is the least reproducible measurement in the workflow.

Failure modes

  • • One-arm screen described as a synthetic lethality screen. It finds dependencies, not interactions.
  • • Interaction measured only in complete medium. The nutrient removed the requirement.
  • • Panel correlation without an isogenic test. Confounded by lineage.
  • • Compound-only evidence. Off-target effects in a chemotype that also inhibits a parallel enzyme.
  • • Effect reported as binary. Most metabolic interactions are graded; the effect size and its confidence interval are the result.
  • • Biomarker assay not validated at the cut-off. The eligible population is defined by the least reliable step.

Where this connects

  • • Tumour metabolic dependency article supplies the four-gate target validation sequence this evidence standard supports.
  • • Amino acid pillar supplies the one-carbon and methionine cycle logic behind the MTAP–MAT2A axis.
  • • Disease pillar supplies the environment frame: dependency and interaction are both properties of a medium and a tissue.
  • • Operationally, library choice, coverage and scoring for the screen itself are in the companion article on designing a synthetic lethality screen.

Scientific interpretation and experimental design

  • • A synthetic lethal interaction needs two arms. Design for the pair or do not use the term.
  • • Separate interaction from sensitisation. They imply different clinical strategies.
  • • Metabolic interactions are conditional. Report the medium and the nutrient supply.
  • • Isogenic pairs are the cheapest decisive test. Panel correlations are not.
  • • Two clones, two guides. Clone-level artefacts are common.
  • • The margin is the mechanism. Most metabolic interactions are graded.
  • • Validate the biomarker at its cut-off. That is where enrolment is decided.

Selected references for further reading

  • • Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nature Reviews Cancer. 2005;5:689–698.
  • • Kryukov GV, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351:1214–1218.
  • • Mavrakis KJ, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science. 2016;351:1208–1213.
  • • Oike T, et al. Molecular mechanisms of synthetic lethality and their application to cancer therapy. Cancer Science. 2017;108:1–11.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: